A first-in-human Phase I trial assessing safety, tolerability and immunomodulatory effects of Foralumab in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Foralumab (Primary)
- Indications Amyotrophic lateral sclerosis; Multiple sclerosis; Neurodegenerative disorders
- Focus Adverse reactions; First in man; Proof of concept
- 30 Sep 2019 According to a Tiziana Life Sciences media release, this study has been completed in September 2019.
- 30 Sep 2019 Status changed from recruiting to completed, according to a Tiziana Life Sciences media release.
- 10 Sep 2019 Results presented in the Tiziana Life Sciences media release.